Monash IVF now expects its underlying net profit after tax for FY26 to land between $17 million and $18 million, lower than previously guided. Management links the downgrade to softer assisted reproductive technology activity in the second half, which is weighing on earnings momentum.
Weaker demand at home comes just as the group pushes hard on efficiency and performance. That mix of falling volumes and internal restructuring sets up a tricky near-term year.
Australian ART market cycle volumes fell 4.7% in the three months to April on a year-on-year basis, and that softer trend is expected to extend through May and June. Monash IVF reports that despite the decline in overall activity it lifted its domestic market share by 1 percentage point to 20.1% over the same quarter.
Total FY26 treatment volumes are now expected to be materially higher than last year, helped by stronger international operations. Offshore clinics are doing more of the heavy lifting while the Australian market cools.
Operational and cost-efficiency programmes are already in motion across the group, targeting lower overheads and sharper clinical performance. Management expects the financial benefits from these initiatives to come through more noticeably in FY27 rather than in the current year.
The strategy trades short-term margin pressure for a leaner cost base and better utilisation over time. Investors now have to weigh a softer FY26 profit line against the promise of higher volumes and efficiency gains down the track.
